 |
市场调查报告书
商品编码
1728478
干癣性关节炎市场:KOL的洞察KOL Insight - Psoriatic Arthritis |
||||||
本报告全面分析了银屑病关节炎 (PsA) 的现有和新兴治疗策略，为不断发展的治疗格局提供了宝贵的见解。报告强调了TNF抑制剂的持久作用以及对IL-17和IL-23抑制剂日益增长的偏好，尤其是在皮肤和眼部症状突出的病例中。此外，报告也探讨了由于疗效提高和易用性增强，从旧疗法转向新型IL-23抑制剂的趋势。透过关键意见领袖 (KOL) 的专家意见，报告全面概述了这些治疗转变如何塑造PsA管理的未来。
关键问题解答
- 目前推荐的干癣性关节炎 (PsA) 治疗方法是什么？
- 抗IL17和抗IL23等新疗法有何不同？
- JAK抑制剂和TYK2抑制剂等口服药物在目前的治疗模式中处于什么位置？
- 哪些患者因素对干癣性关节炎（PsA）的治疗选择影响最大？
- 支付方压力将如何影响KOL的决策？
- 抗TNF和JAK抑制剂的生物相似药将如何影响PsA的治疗方案？
- 哪些仿製药最受KOL的关注？
- 在研药物需要具备哪些优势才能与市场领导者竞争？
- 目前PsA的诊断和治疗有哪些差距？
- 未来3-5年，PsA的治疗模式预计将如何变化？
领导品牌
|
|
|
部分参与专家名单
- 德州大学西南医学中心临床医学教授，达拉斯长老会医院风湿病科联合主任德州
- 哈佛医学院布莱根妇女医院临床风湿病学联合主任，蒙彼利埃大学医学教授，麻萨诸塞州波士顿
- 纽约阿尔伯特爱因斯坦医学院医学院临床副教授
- 英国利兹大学风湿病学教授，利兹NIHR生物医学研究中心主任
- 荷兰阿姆斯特丹联合医疗中心风湿病学和临床免疫学主任，教授
- 法国蒙彼利埃大学蒙彼利埃中心风湿病学教授，风湿病学主任，骨关节医学和外科主任
方法
"治疗趋势" 报告透过对全球领先的关键意见领袖 (KOL) 进行深入访谈，就关键疾病领域的当前和未来治疗前景进行总结。我们根据严格的筛选标准，精心挑选关键意见领袖 (KOL)，这些标准涵盖全球声誉、临床专业知识以及在治疗领域的影响力。每次访谈都附有精心设计的讨论指南。这些指南由我们与关键意见领袖合作制定，并由行业专家进行同行评审，以确保所提问题全面且与当前市场动态相关。每份报告发布后，我们都会持续进行12个月的市场监测，并及时提供来自关键意见领袖的重大新闻事件、市场变化和市场发展动态的更新。
我们的报告有何特别之处？
FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供详细且可操作的洞察。我们深厚的行业知识使我们能够为您提供相关且有价值的洞察，帮助您掌握新兴趋势并有效应对复杂课题。凭藉广泛的研究以及来自顶尖专家和关键意见领袖的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家独家访谈和数据，以及持续的市场监测，确保您全面了解市场动态。我们的报告涵盖 40 多个活跃疾病领域，汇集医生情报（包括 KOL 洞察和定量医生调查），以及行业专家对医疗事务、数位医疗、销售与市场营销、市场准入及其他领域问题的看法，助您做出更明智的数据驱动决策，在快速变化的行业中保持竞争力。
This report provides a comprehensive analysis of the current and emerging treatment strategies for Psoriatic Arthritis (PsA), offering valuable insights into the evolving therapeutic landscape. It highlights the enduring role of TNF inhibitors and the rising preference for IL-17 and IL-23 inhibitors, particularly in cases with significant skin or ocular symptoms. Additionally, the report explores the shift from older therapies to newer IL-23 inhibitors, driven by their improved efficacy and ease of use. Through expert opinion from key opinion leaders (KOLs), this report offers a comprehensive overview of how these treatment shifts are shaping the future of PsA management.
Key Questions Answered:
- 1. What are the preferred current treatments for Psoriatic Arthritis (PsA)?
- 2. How do newer treatments like anti-IL17s and anti-IL23s compare to each other?
- 3. Where do oral therapies like JAK and TYK2 inhibitors stand in the current treatment landscape?
- 4. What patient factors most significantly influence PsA therapy choices?
- 5. How do payer pressures shape the decisions of key opinion leaders (KOLs)?
- 6. What impact will biosimilar anti-TNFs and JAK inhibitors have on the PsA treatment algorithm?
- 7. Which late-stage drug candidates are generating the most interest among KOLs?
- 8. What must pipeline drugs demonstrate to compete with market leaders?
- 9. What are the current gaps in PsA diagnosis and management?
- 10. How is the PsA treatment landscape expected to change in the next three to five years?
Key Brands:
|
|
|
Partial List of Participating Experts:
- Clinical Professor in the Department of Internal Medicine, UT Southwestern Medical Center, Co-Director of the Division of Rheumatology at Presbyterian Hospital, Dallas, TX
- Co-Director, Clinical Rheumatology, Brigham and Women's Hospital and Professor of Medicine, Harvard Medical School, Boston, MA
- Clinical Associate Professor, Department of Medicine, Albert Einstein College of Medicine, NY
- Director of the Leeds NIHR Biomedical Research Centre, Professor of Rheumatology, University of Leeds, Leeds, UK
- Professor, Chair of the Department of Rheumatology and Clinical Immunology at the Amsterdam UMC, Amsterdam, Netherlands
- Professor of Rheumatology, Head of the department of Rheumatology, Head of the medical and surgical bones and joint departments, Montpellier University, CHU Montpellier, France
Methodology:
Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
